Severe hypertriglyceridemia is a condition characterized by extremely high triglyceride levels, typically exceeding 500 mg/dL, posing serious risks such as pancreatitis and cardiovascular complications. It accounts for a significant share of lipid disorders, with about one-third of U.S. adults exhibiting elevated triglyceride levels. The severe hypertriglyceridemia pipeline analysis by Expert Market Research highlights ongoing advancements in biologics and gene-targeted therapies. Rising awareness, improved diagnostics, and investment in R&D are expected to drive the growth of severe hypertriglyceridemia therapeutics in the coming years.
Major companies involved in the severe hypertriglyceridemia pipeline analysis include Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, and others.
Leading drugs currently in the pipeline include Olezarsen, Plozasiran Injection, DR10624, and others.
The rising clinical focus on lipid pathway mechanisms, supportive regulatory frameworks for rare metabolic conditions, and improved early detection through advanced diagnostics are driving the severe hypertriglyceridemia pipeline growth.
The Severe Hypertriglyceridemia Pipeline Analysis Report by Expert Market Research gives comprehensive insights into severe hypertriglyceridemia therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Severe Hypertriglyceridemia. The severe hypertriglyceridemia report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The severe hypertriglyceridemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with severe hypertriglyceridemia treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to severe hypertriglyceridemia.
Severe hypertriglyceridemia is a condition characterized by extremely high levels of triglycerides in the blood, often exceeding 1,000 mg/dL. It occurs due to genetic factors, uncontrolled diabetes, obesity, excessive alcohol intake, or certain medications. This condition can lead to life-threatening complications, such as acute pancreatitis, when not properly managed.
Severe hypertriglyceridemia treatment includes triglyceride-lowering medications, strict dietary fat restrictions, and lifestyle changes. Fibrates, omega-3 fatty acids, and statins are commonly prescribed to reduce triglyceride levels and prevent complications. In December 2024, Olezarsen (Tryngolza), an antisense oligonucleotide, became the first FDA-approved drug for familial chylomicronemia syndrome, significantly lowering triglycerides and reducing pancreatitis risk in affected adults.
Severe hypertriglyceridemia affects approximately 1 in 600 individuals in the United States, with about 2.3 million adults having triglyceride levels ≥500 mg/dL. Its prevalence is higher among men aged 40-60 years and Hispanic populations. Around 70.3% of affected individuals have central obesity, and 29.3% present with multiorgan disease. Compared to those with triglycerides <200 mg/dL, the adjusted prevalence ratio for multiorgan disease is 2.95 in severe cases.
This section of the report covers the analysis of severe hypertriglyceridemia drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III holds the largest share at 90%, showcasing strong late-stage development in the severe hypertriglyceridemia pipeline. Phase II accounts for 10%, indicating continued innovation and progress. The dominance of advanced clinical phases reflects a promising landscape that may lead to effective treatments, positively impacting market growth and improving patient outcomes.
The drug molecule categories covered under the severe hypertriglyceridemia pipeline analysis include small molecules, antisense oligonucleotides, siRNA, monoclonal antibodies, gene therapies, and others. The severe hypertriglyceridemia report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for severe hypertriglyceridemia.
RNA-based drug therapies are emerging as a novel approach in the severe hypertriglyceridemia pipeline. For instance, Lipisense, a liver-specific RNA therapeutic developed by Lipigon Pharmaceuticals, is currently in Phase II clinical trials. It targets angiopoietin-like 4 (ANGPTL4) to enhance triglyceride clearance, offering potential benefits for patients with severe lipid imbalances and type 2 diabetes.
The EMR report for the severe hypertriglyceridemia pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed severe hypertriglyceridemia therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in severe hypertriglyceridemia clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for severe hypertriglyceridemia. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of severe hypertriglyceridemia drug candidates.
Olezarsen is currently being evaluated in a Phase III trial sponsored by Ionis Pharmaceuticals, Inc. for patients with severe hypertriglyceridemia (sHTG). Olezarsen is a ligand-conjugated antisense (LICA) RNA-targeted therapy that inhibits apoC-III production, a key regulator of triglyceride metabolism. This study is assessing the efficacy of subcutaneous Olezarsen versus placebo in reducing fasting triglyceride levels.
Plozasiran is being sponsored by Arrowhead Pharmaceuticals for a Phase III study (SHASTA-4) to evaluate its safety and efficacy in adults with severe hypertriglyceridemia (SHTG). The study is assessing whether Plozasiran, an RNA interference (RNAi) therapeutic targeting APOC3, can significantly lower triglyceride levels by inhibiting its production and restoring lipid balance.
DR10624 is a long-acting Fc fusion protein tri-agonist developed by Zhejiang Doer Biologics Co., Ltd. It targets GLP-1R, GCGR, and FGF21R receptors for metabolic improvement. This Phase II study is evaluating its efficacy and safety in treating severe hypertriglyceridemia (SHTG). The trial is examining how DR10624 reduces fasting serum triglyceride levels over 12 weeks.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Severe Hypertriglyceridemia Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for severe hypertriglyceridemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into severe hypertriglyceridemia collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share